Serge
Patient
Bladder cancer treatment has entered a transformative era with Padcev (enfortumab vedotin) and Keytruda (pembrolizumab), a groundbreaking combination recently approved by Health Canada. This innovative therapy is transforming outcomes for patients with metastatic urothelial cancer, offering hope for patients who previously faced limited treatment options.
Historically, advanced bladder cancer treatment relied heavily on chemotherapy, which often provided short-term benefits and came with significant side effects. Padcev is a treatment which attacks bladder cancer cells by targeting a specific protein, while Keytruda enhances the immune system’s ability to attack cancer cells. Together, they create a powerful synergy.
This combination has dramatically improved patient outcomes, delaying disease progression and increasing overall survival. The response rate has shown an impressive 68%, with 29% of patients achieving complete remission.
While the combination is a game-changer, it does have side effects, including skin toxicity, neuropathy, high blood sugar, and gastrointestinal issues. Early recognition and management are essential to maintaining quality of life.
Serge, a patient who underwent Padcev + Keytruda treatment, shared his experience: “The quality of life has surpassed my expectations. I’ve been able to golf and walk the course three times a week this summer. It’s about adjusting and allowing time to rest, but overall, it’s been a positive experience.”
Looking ahead, researchers are exploring the use of this combination in earlier stages of bladder cancer, and are exploring other targeted therapies to further personalize treatment.
This breakthrough represents a significant leap forward, offering hope for improved outcomes and quality of life for patients. As advocacy and education continue to play a vital role, the future of bladder cancer care looks brighter than ever.
To find support or learn more, contact Bladder Cancer Canada today or visit bladdercancercanada.org.
